Online citations, reference lists, and bibliographies.

Ileal Neuroendocrine Tumors And Heart: Not Only Valvular Consequences

Jan Calissendorff, Eva Maret, Anders Sundin, Henrik Falhammar
Published 2014 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Ileal neuroendocrine tumors (NETs) often progress slowly, but because of their generally nonspecific symptoms, they have often metastasized to local lymph nodes and to the liver by the time the patient presents. Biochemically, most of these patients have increased levels of whole blood serotonin, urinary 5-hydroxyindoleacetic acid, and chromogranin A. Imaging work-up generally comprises computed tomography or magnetic resonance imaging and somatostatin receptor scintigraphy, or in recent years positron emission tomography with 68Ga-labeled somatostatin analogs, allowing for detection of even sub-cm lesions. Carcinoid heart disease with affected leaflets, mainly to the right side of the heart, is a well-known complication and patients routinely undergo echocardiography to diagnose and monitor this. Multitasking surgery is currently recognized as first-line treatment for ileal NETs with metastases and carcinoid heart disease. Open heart surgery and valve replacement are advocated in patients with valvular disease and progressive heart failure. When valvulopathy in the tricuspid valve results in right-sided heart failure, a sequential approach, performing valve replacement first before intra-abdominal tumor-reductive procedures are conducted, reduces the risk of bleeding. Metastases to the myocardium from ileal NETs are seen in <1–4.3 % of patients, depending partly on the imaging technique used, and are generally discovered in those affected with widespread disease. Systemic treatment with somatostatin analogs, and sometimes alpha interferon, is first-line medical therapy in metastatic disease to relieve hormonal symptoms and stabilize the tumor. This treatment is also indicated when heart metastases are detected, with the addition of diuretics and fluid restriction in cases of heart failure. Myocardial metastases are rarely treated by surgical resection.
This paper references
10.1016/j.bpg.2013.01.001
Biotherapies for GEP-NETs.
Kjell E Öberg (2012)
Montravers , 18 Ffluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type
J. N. Talbot (2007)
location, metastasis, clinical manifestations, diagnostic approaches and therapeutic considerations
K. A. Ekmektzoglou (2008)
10.4065/77.6.591
Isolated metastatic myocardial carcinoid tumor in a 48-year-old man.
Vijaykumar S. Kasi (2002)
10.2459/JCM.0b013e3282f88e49
Heart and tumors: location, metastasis, clinical manifestations, diagnostic approaches and therapeutic considerations
Konstantinos Ekmektzoglou (2008)
10.1159/000335597
ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary
Marianne E. Pavel (2011)
10.1002/jso.10062
Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature.
Wey L Leong (2002)
10.1016/s0022-5223(19)35500-x
Surgical treatment of carcinoid heart disease.
Lars-G. Lundin (1990)
10.1159/000318014
Activin A in Carcinoid Heart Disease: A Possible Role in Diagnosis and Pathogenesis
Deidi Strickland Bergestuen (2010)
10.1016/j.ejcts.2010.10.035
Outcomes, risks and complications of cardiac surgery for carcinoid heart disease.
S. Bhattacharyya (2011)
10.1016/S0733-8651(05)70184-3
Transesophageal echocardiographic (TEE) evaluation of intracardiac and pericardial masses.
Jonathan H. Goldman (2000)
10.1002/cncr.20659
Carcinoid metastasis to the brain.
R. Hlatký (2004)
Expression of 5-hydroxytryptamine receptor subtype messenger RNA in interstitial cells from human heart valves.
A. Roy (2000)
10.1200/JCO.2009.22.8510
Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group.
R. Arnold (2009)
Two Case Reports and Review of the Literature
Joanne Kurtzberg (1987)
10.1080/AC.65.6.2059873
An unusual cause of carcinoid heart disease
Peter Haemers (2010)
10.1055/s-0030-1267204
A matter of the heart: myocardial metastases in neuroendocrine tumors.
H. Jann (2010)
10.1016/S0735-1097(98)00354-4
Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease.
W D Denney (1998)
10.1148/rg.342135504
Midgut neuroendocrine tumors: imaging assessment for surgical resection.
Lorna Woodbridge (2014)
10.1177/1094428107303161
Meta-Analysis
Frank W. Schmidt (2008)
Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects.
Nalini M Rajamannan (2001)
incidence and relevance
D. J. Kwekkeboom (2014)
10.1056/NEJMoa1316158
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Martyn Evan Caplin (2014)
10.1007/s12020-014-0272-4
Myocardial metastases from neuroendocrine tumors: incidence and relevance
Dik J. Kwekkeboom (2014)
lessons from a case series
S. V. Pislaru (2014)
10.1200/JCO.2009.22.8510
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
A. Rinke (2009)
10.1007/s00268-002-6628-6
Treatment of Small Intestinal Neuroendocrine Tumors: Is an Extended Multimodal Approach Justified?
Martin Schindl (2002)
myocardial metastases of carcinoid visualized by 18F-dihydroxy-phenyl-alanine positron emission tomography
H. B. Fiebrich (2008)
Broelsch, The impact of 68GaDOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors
A. Frilling (2010)
10.1016/0002-9343(90)90194-I
Carcinoid tumor metastatic to the heart.
Steven N Fine (1990)
10.1007/s12020-013-0108-7
68Ga-DOTA-TOC-PET/CT detects heart metastases from ileal neuroendocrine tumors
Jan Calissendorff (2013)
10.1016/S0735-1097(02)02109-5
Metastatic carcinoid tumor to the heart: echocardiographic-pathologic study of 11 patients.
U H Pandya (2002)
10.2214/ajr.140.5.903
CT of intracardiac and intrapericardial masses.
Barry H. Gross (1983)
10.1093/eurheartj/ehl237
Myocardial metastasis of a bronchial carcinoid.
S. Maréchaux (2007)
10.1016/j.amjcard.2010.12.025
Risk factors for the development and progression of carcinoid heart disease.
S. Bhattacharyya (2011)
10.1161/CIRCULATIONAHA.111.037606
Multimodality imaging in an unusual case of palpitations and right heart failure.
Ken J Lu (2011)
initial experience
E. G. Amparo (1984)
10.1161/01.CIR.87.4.1188
Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients.
P. Pellikka (1993)
10.1200/JCO.2008.19.9232
Solitary myocardial metastasis from small-bowel neuroendocrine carcinoma.
C. Patel (2009)
10.1530/ERC-14-0173
Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide.
M. H. Kulke (2014)
Krenning, Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors
D. J. Kwekkeboom (2010)
10.1016/0002-8703(86)90369-8
Unusual cardiac involvement in carcinoid syndrome.
Vicki L. Schiller (1986)
68 Ga - DOTANOC PET / CT clinical impact in patients with neuroendocrine tumors
G. C. Sotiropoulos Frilling
10.1016/j.freeradbiomed.2007.03.036
MAO-A-induced mitogenic signaling is mediated by reactive oxygen species, MMP-2, and the sphingolipid pathway.
C. Coatrieux (2007)
Montravers , 18 Ffluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type
J. N. Talbot (2007)
10.1016/j.amjcard.2006.07.092
Carcinoid heart disease in patients without hepatic metastases.
Alain Marcel Bernheim (2007)
10.1200/JCO.2008.18.7047
Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor.
C M Korse (2009)
10.1097/jnn.0b013e318274cc4d
A Review of the
Robert Wolpert (1985)
is an extended multimodal approach justified? World J
M. Schindl (2002)
10.1016/0735-1097(94)00374-Y
Outcome of cardiac surgery for carcinoid heart disease.
H. Connolly (1995)
10.1161/CIRCULATIONAHA.105.553750
Prognosis of Carcinoid Heart Disease: Analysis of 200 Cases Over Two Decades
Jacob Eifer Møller (2005)
Carcinoid tumors in the gastrointestinal tract--an analysis of 156 cases.
Hans Mårtensson (1983)
The impact of 68 GaDOTATOC positron emission tomography / computed tomography on the multimodal management of patients with neuroendocrine tumors
G. C. Sotiropoulos A. Frilling (2010)
Caplin, Carcinoid heart disease
S. Bhattacharyya (2007)
10.1046/j.0007-1323.2001.01798.x
Prediction of prognosis by echocardiography in patients with midgut carcinoid syndrome.
G. Westberg (2001)
10.2967/jnumed.109.071712
68Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors
V. Ambrosini (2010)
10.1016/j.amjcard.2008.05.047
Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease.
S. Bhattacharyya (2008)
a meta-analysis
G. Treglia (2012)
10.1161/01.CIR.0000159356.42064.48
Long-Term Serotonin Administration Induces Heart Valve Disease in Rats
B. Gustafsson (2005)
10.1016/S1062-1458(02)00927-3
Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy.
Frank Grothues (2002)
ges in cardiovascular medicine : myocardial metastases of carcinoid visualized by 18 Fdihydroxyphenylalanine positron emission tomography
A. H. Brouwers H. B. Fiebrich (2010)
10.4065/77.2.139
Surgical pathology of carcinoid heart disease: a study of 139 valves from 75 patients spanning 20 years.
Daniel V. Simula (2002)
10.1016/j.amjcard.2007.11.056
Prevalence of patent foramen ovale and usefulness of percutaneous closure device in carcinoid heart disease.
Nicolas Mansencal (2008)
10.1093/oxfordjournals.eurheartj.a060894
Cardiac manifestations in mid-gut carcinoid disease.
Morten Jacobsen (1995)
10.1016/j.ahj.2006.02.019
Assessment of patent foramen ovale in carcinoid heart disease.
Nicolas Mansencal (2006)
10.1007/s11845-008-0273-5
Cardiac carcinoid: tricuspid delayed hyperenhancement on cardiac 64-slice multidetector CT and magnetic resonance imaging
Ramón Carmona Martos (2010)
10.1067/j.cpradiol.2008.05.003
Non-electrocardiogram-gated multidetector-row computed tomography findings of cardiac pathology in oncologic patients.
Maria Lourdes Díaz (2009)
10.1093/eurheartj/ehr089
Quadruple valve replacement for valve destruction in carcinoid heart disease.
Elisa McAlindon (2011)
10.1177/030089160008600119
Primary Carcinoid Tumor of the Ovary: Report of an Unusual Case
Tony Sabatini (2000)
American Society of Echocardiography , European Association of , Echocardiography , EAE / ASE recommendations for image acquisition and display using three - dimensional echocardiography
A. Bernheim
Kvols, Outcome of cardiac surgery for carcinoid heart disease
H. M. Connolly (1995)
10.1001/archinte.1953.00240140084007
Secondary tumors of heart and pericardium; review of the subject and report of one hundred thirty-seven cases.
J. F. Deloach (1953)
10.1152/ajplung.1999.277.2.L282
Serotonin stimulates mitogen-activated protein kinase activity through the formation of superoxide anion.
Sheu-Ling Lee (1999)
myocardial metastases in neuroendocrine tumors
H. Jann (2010)
does valve replacement permit safe hepatic resection? J
J. B. Lillegard (2011)
10.1007/s00268-002-6630-z
Effect of Surgery on the Outcome of Midgut Carcinoid Disease with Lymph Node and Liver Metastases
Per Hellman (2002)
10.1016/j.carpath.2011.10.003
Solitary atrial myocardial metastasis revealing ileal neuroendocrine carcinoma.
Jonathan Meurice (2012)
10.1016/j.amjcard.2009.10.023
Comparison of prognostic value of tissue Doppler imaging in carcinoid heart disease versus the value in patients with the carcinoid syndrome but without carcinoid heart disease.
Nicolas Mansencal (2010)
10.14797/MDCJ-6-3-4
Evaluation of cardiac masses: the role of cardiovascular magnetic resonance.
D. Shah (2010)
10.1007/978-3-642-27994-2_20
Rare metastases detected by (68)Ga-somatostatin receptor PET/CT in patients with neuroendocrine tumors.
C. Carreras (2013)
10.1007/BF02713859
Serotonin uptake and metabolism in isolated, perfused fetal, newborn and adult rabbit lungs
E. Burt Olson (2007)
10.1002/clc.20260
Magnetic resonance imaging of carcinoid heart disease.
Damian Franzen (2009)
10.1016/j.jtcvs.2009.07.072
Surgical excision of right ventricular carcinoid tumor in a symptomatic patient without carcinoid valve disease.
Basar Sareyyupoglu (2010)
Pellikka , Carcinoid heart disease
A. M. Bernheim (1991)
tricuspid delayed hyperenhancement on cardiac 64-slice multidetector CT and magnetic resonance imaging
R. Martos (2010)
Pellikka, Role of hepatic resection for patients with carcinoid heart disease
A. M. Bernheim (2008)
analysis of 200 cases over two decades
J. E. Moller (2005)
10.1152/ajpheart.00570.2009
Serotonin produces monoamine oxidase-dependent oxidative stress in human heart valves.
Ricardo A. Peña-Silva (2009)
10.1007/s00259-013-2342-x
18F-Fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type
Sona Balogova (2013)
10.1097/00000658-198708000-00001
Malignant Carcinoid Tumors An Analysis of 103 Patients with Regard to Tumor Localization, Hormone Production, and Survival
Ingrid Norheim (1987)
10.1200/JCO.2007.15.4377
One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.
James C. Yao (2008)
10.1002/clc.4960090104
Heart involvement in metastatic carcinoid disease.
K. Törnebrandt (1986)
10.1056/NEJMc1409757
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Feng Yang (2014)
imaging assessment for surgical resection
L. R. Woodbridge (2014)
a mechanism for serotonin effects
N. M. Rajamannan (2001)
10.1002/jmri.10164
Comparison of right ventricular volume measurement between segmented k-space gradient-echo and steady-state free precession magnetic resonance imaging.
K. Alfakih (2002)
10.1097/MPA.0b013e3181ebaffd
NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine Tumor
Aaron I Vinik (2010)
CT and MR imaging
C. Chiles (2001)
10.1159/000111037
Consensus Guidelines for the Management of Patients with Liver Metastases from Digestive (Neuro)endocrine Tumors: Foregut, Midgut, Hindgut, and Unknown Primary
Thomas Steinmüller (2007)
Clinical Review
Mark K. Wax (1839)
10.1161/CIRCULATIONAHA.107.701367
Carcinoid Heart Disease
S. Bhattacharyya (2007)
10.1007/s11936-013-0265-2
Carcinoid Valve Disease
J. Wells Askew (2013)
10.1016/j.jamcollsurg.2011.03.029
Hepatic resection for the carcinoid syndrome in patients with severe carcinoid heart disease: does valve replacement permit safe hepatic resection?
Joseph Benjamin Lillegard (2011)
10.1016/j.echo.2009.11.016
Dynamic assessment of right ventricular volumes and function by real-time three-dimensional echocardiography: a comparison study with magnetic resonance imaging in 100 adult patients.
Gregor Leibundgut (2010)
Fanburg , Serotonin stimulates mitogen - activated protein kinase activity through the formation of superoxide anion
L. B. (1999)
10.1007/978-0-387-75587-8_7
Imaging cardiac tumors.
Mannudeep K. Kalra (2008)
10.1148/radiographics.21.2.g01mr15439
Metastatic involvement of the heart and pericardium: CT and MR imaging.
Caroline Chiles (2001)
10.1055/s-2005-858489
[Heart tumors: magnetic resonance imaging and multislice spiral CT].
Gabriele Anja Krombach (2005)
Sivananthan, Comparison of right ventricular volume measurement between segmented k-space gradient-echo and 24 steady-state free precession magnetic resonance imaging
K. Alfakih (2002)
Pellikka, Factors associated with progression of carcinoid heart disease
J. E. Moller (2003)
10.1159/000111034
Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors – Well-Differentiated Jejunal-Ileal Tumor/Carcinoma
B. Eriksson (2007)
10.1007/s12020-012-9631-1
Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis
G. Treglia (2012)
10.2967/jnumed.106.035667
68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT
M. Gabriel (2007)
10.1016/j.jacc.2007.12.036
Early and late results of valvular surgery for carcinoid heart disease.
Javier G. Castillo (2008)
10.1159/000335629
ENETS Consensus Guidelines for the Management of Patients with Neuroendocrine Neoplasms from the Jejuno-Ileum and the Appendix Including Goblet Cell Carcinomas
U. Pape (2011)
10.1016/j.crad.2008.10.013
Cardiovascular magnetic resonance imaging in the assessment of carcinoid heart disease.
Holger Sandmann (2009)
Byrd 3 rd , Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease
H. M. Connolly (1998)
Erd - mann , Magnetic resonance imaging of carcinoid heart disease
A. Boldt D. Franzen (2009)
10.2214/ajr.143.6.1151
Gated MRI of cardiac and paracardiac masses: initial experience.
Eugenio G. Amparo (1984)
10.1097/SLA.0b013e3181fd37e8
The Impact of 68Ga-DOTATOC Positron Emission Tomography/Computed Tomography on the Multimodal Management of Patients With Neuroendocrine Tumors
Andrea Frilling (2010)
10.1136/gutjnl-2011-300831
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)
J. Ramage (2011)
10.1056/NEJMoa021451
Factors associated with progression of carcinoid heart disease.
J. Møller (2003)
10.1016/j.echo.2005.10.015
The echocardiographic evaluation of intracardiac masses: a review.
Priscilla J. Peters (2006)
10.1093/ejcts/ezu201
Misconceptions, diagnostic challenges and treatment opportunities in bioprosthetic valve thrombosis: lessons from a case series.
Sorin V. Pislaru (2015)
update on systematic review and metaanalysis
H. Geijer (2013)
A report of an unusual case
Giovanni Capasso (1998)
[Advantages of transesophageal color Doppler echocardiography in the diagnosis and surgical treatment of cardiac masses].
Masahiko Matsumura (1990)
10.5935/2318-8219.20140013
Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography
L. Rudski (2014)
10.1016/j.echo.2011.11.010
EAE/ASE recommendations for image acquisition and display using three-dimensional echocardiography.
Roberto M. Lang (2012)
10.1172/JCI117090
Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.
Atsuko Kubota (1994)
10.1016/j.ahj.2013.09.012
The role of cardiovascular magnetic resonance imaging and computed tomography angiography in suspected non-ST-elevation myocardial infarction patients: design and rationale of the CARdiovascular Magnetic rEsoNance imaging and computed Tomography Angiography (CARMENTA) trial.
Martijn W. Smulders (2013)
American Society of Echocardiography , European Association of , Echocardiography , EAE / ASE recommendations for image acquisition and display using three - dimensional echocardiography
M. Handke (2012)
10.1016/j.amjcard.2004.01.075
Carcinoid heart disease associated with primary ovarian carcinoid tumor.
Nithima Chaowalit (2004)
10.1634/theoncologist.10-2-123
Metastatic carcinoid tumors: a clinical review.
Johanna Maria Zuetenhorst (2005)
10.1259/bjr/16301537
Imaging the heart valves using ECG-gated 64-detector row cardiac CT.
Nathan E. Manghat (2008)
10.4065/83.2.143
Role of hepatic resection for patients with carcinoid heart disease.
Alain Marcel Bernheim (2008)
10.1016/0002-8703(91)90045-J
Bioprosthetic tricuspid valve stenosis associated with extensive plaque deposition in carcinoid heart disease.
P. Ridker (1991)
10.1177/003591577406700501
Carcinoid Heart Disease
Shaival H. Davé (1974)
Montravers , 18 F - fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type
V. Huchet (2013)
Effect of hemorrhagic shock on 5-hydroxytryptamine removal by the lung.
Morris D. Kerstein (1982)
10.1002/cncr.25049
The 5-HT(2B) receptor plays a key regulatory role in both neuroendocrine tumor cell proliferation and the modulation of the fibroblast component of the neoplastic microenvironment.
Bernhard Svejda (2010)
10.1007/s00259-013-2482-z
Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis
Håkan Geijer (2013)
10.1530/ERC-13-0152
The optimal use of cardiac imaging in the quantification of carcinoid heart disease.
Rebecca Dobson (2013)
10.1186/1471-2407-10-6
Plasma CCN2/connective tissue growth factor is associated with right ventricular dysfunction in patients with neuroendocrine tumors
Deidi Strickland Bergestuen (2009)
10.1053/j.semnuclmed.2009.10.004
Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
D. Kwekkeboom (2010)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar